Develop in and out licensing for biotech and Pharmaceutical companies

Protect develops the cutting edge technology for animal healths

Angel Investment fund and consulting firm for business development specialized in Life Science and Medical device industry.Angel investment with consulting service developing out licensing and fund-raising activities for Life science companies. • Assisted to introduce 5 Top 10 global pharmaceutical companies conducted DD process for L pharma, 1 Top 10 global pharma provided term-sheet and is in the negotiation process.• Successfully signed 15 NDAs from global pharmaceutical companies for C pharma to go into DD process, among them 5 of the NDAs are from Top 10 global pharmaceutical companies. • Bridged a Japanese medical device giant to contract a potential M&A deal in the future for E medical device company. • Strong relationship to 6 Top 20 global pharmaceutical companies licensing team. • Brought 5 companies roadshow to global BIO tradeshows including BIO US, Europe, Asia, China, and JPM conferences.• Board member on Panlabs Biologics Inc. and MountainVet Biotech Co., LTD.

https://coastartherapeutics.com/

1. Manage the manufacturing site of 20+ personnel for Microbio pharmaceutical plant in Shanghai, China. 2. Develop and discover business opportunities and strategic alliances for Microbio group. 3. Discover investment opportunities for Diamond Biofund.

Led the investment team to Taiwan's largest biotech evergreen fund which was founded in 2013 with AUM $333M USD. Diamond BioFund is a subsidiary of Microbio Group with $1,600M USD net assets.• Portfolio Management: Successfully sourced 11 cases with total value of $80M USD since fund inception, co-chaired all due diligence and negotiation of terms. More than half of the cases currently value average 2x cost with average 141.02% ROI; served on the board of one portfolio company; guided two deals to Taiwan GreTai Security Market with capital gain of 46.67% and two impending IPO cases which will result in market cap at $451M USD.• Investment Strategy: Developed and implemented overall investment strategy, investment guideline, valuation models and due diligence standard procedure, resulted in deals size between $2M and $65M USD and valuation size ranging from $20M to $266M USD.• Organizational Development: Currently heading the drug development and new therapeutic area practice within the group with 5 new drugs / cell therapy companies in portfolio from the newest glycan technology, drug delivery system, to stem cell therapy development with total value of $59M USD and ROI 214.16%; assisted in recruiting the management team and provided extensive coaching to junior members with recognition from senior management. • Operations: Gained cross companies operating experience within Microbio Group by building the bakery business unit and improving the quality of a major product line for the largest health food channel in Taiwan; the result increased company revenue by 3% and 25% improvement on customer satisfaction survey in 3 months. Coordinated and negotiated the flagship diabetic foot product’s out-licenses deal for one of the public subsidiary companies; engaged two interested Chinese buyers with potential deal size of $16M USD.

Pharmigene is established in 2005 and funded by venture capital firms and individuals. Our goal is to innovate and commercialize diagnostic tests that enable individuals to be better informed about their genomic makeup and to make decisions that better their health. We have licensed exclusive world-wide rights and transferred key know-how from Academia Sinica relating to the genetic markers that are associated with adverse drug reactions caused by several popular drugs. We have obtained ISO 13485 / 9001 and GMP certifications, and are manufacturing our DNA genetic tests under the most stringent guideline. In developing our DNA genetic tests, we also have validated our tests with clinical studies that involved hundreds and thousands of patients. Today our DNA genetic tests are available world wide. Specifically several of our tests have CE Marking and have obtained IVD clearance from Department of Health in Taiwan.

Built and led biotech sector coverage at First Capital Management, subsidiary of No.5 Financial Holding companies in Taiwan. Underwrote biotech IPO cases and evaluated TWSE biotech sector and developed fundamental research-driven investment theses and sector strategies to clients, including local and international fund managers.• Completed IPO cases including Adimmune(4142), Maxigen(1783), Avita(4735) and raised $35.5M USD capital in total. • Managed biotech stock portfolio increased in a 125% return on investment from 2010 Q3~ 2012 Q4. • Achieved an 89.45% return on investment in 2013, outperformed TWSE market return by 78.17%.

Analyzed and evaluated RSV vaccine's market potential in Greater China; the project was contracted by Astra Zeneca. Analyzed demographic and healthcare market trends in China, including healthcare expenses and the insurance system.Identified and interviewed key opinion leaders of related medical fields including neonatology and pediatric cardiology.

Developed new homeowner insurance policy products, including market analysis, financial analysis, pricing, and marketing strategy

Reported daily news and wrote weekly columns regarding healthcare issues, for Taiwan's leading national newspaper with a readership of 12 million.First in company history to be promoted from Assistant Reporter to Reporter within one year.Investigations included coverage of the SARS and avian flu breakouts in Asia; awarded "the best news investigation in Taiwan for 2003", Taiwan's equivalent of the Pulitzer Prize.Led coverage and authored article on Taiwanese hospital efficiency; nominated for "top 10 most important news reports in Taiwan for 2005", the story was broadcast on television for over two weeks and generated 4 million readers.

Designed and operated defense systems against nuclear, biological and chemical weapons; successfully received NBC certifications. Unit was awarded "best nuclear, biological and chemical defense operating base" of the Department of National Guard.